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Abstract
Background: Hip osteoarthritis (OA) is a common condition leading to pain, disability and reduced quality of life.
There is currently limited evidence to support the use of conservative, non-pharmacological treatments for hip OA.
Exercise and manual therapy have both shown promise and are typically used together by physiotherapists to
manage painful hip OA. The aim of this randomised controlled trial is to compare the efficacy of a physiotherapy
treatment program with placebo treatment in reducing pain and improving physical function.
Methods: The trial will be conducted at the University of Melbourne Centre for Health, Exercise and Sports
Medicine. 128 participants with hip pain greater or equal to 40/100 on visual analogue scale (VAS) and evidence of
OA on x-ray will be recruited. Treatment will be provided by eight community physiotherapists in the Melbourne
metropolitan region. The active physiotherapy treatment will comprise a semi-structured program of manual
therapy and exercise plus education and advice. The placebo treatment will consist of sham ultrasound and the
application of non-therapeutic gel. The participants and the study assessor will be blinded to the treatment
allocation. Primary outcomes will be pain measured by VAS and physical function recorded on the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) immediately after the 12 week intervention. Participants
will also be followed up at 36 weeks post baseline.
Conclusions: The trial design has important strengths of reproducibility and reflecting contemporary physiotherapy
practice. The findings from this randomised trial will provide evidence for the efficacy of a physiotherapy program
for painful hip OA.
Trial Registration: Australian New Zealand Clinical Trials Registry reference: ACTRN12610000439044.
Background
Hip osteoarthritis (OA) is a prevalent chronic musculos-
keletal condition causing pain, disability, and reduced
quality-of-life in affected individuals [1]. There is cur-
rently no cure and total hip joint replacement is com-
mon for advanced disease. Thus hip OA is a major
public health problem contributing to substantial
patient morbidity, health care costs and lengthy surgical
waiting lists.
While conservative non-pharmacological treatments,
such as exercise, are recommended for hip OA [2,3],
unlike knee OA, there is little evidence to support their
effectiveness. Of the hip OA research, 79% of the pub-
lished literature involves surgical treatment [4]. This
lack of evidence has been highlighted by the European
League against Rheumatism (EULAR), a major interna-
tional rheumatology body [4]. Not surprisingly then,
EULAR placed randomised controlled trials of conserva-
tive non-drug treatments as one of its top research prio-
rities for hip OA.
A recent systematic review of land-based exercise for
hip OA combining the results of five clinical trials
demonstrated a small favourable treatment effect for
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function [5]. Similar conclusions were reached by the
authors of another recent systematic review which stated
that there was insufficient evidence to suggest that
exercise therapy alone can be an effective short-term
management approach for reducing pain levels, function,
and quality of life [6]. In contrast, the results of a meta-
analysis of the benefits of exercise, including water-
based programs, for pain relief in hip OA were more
favourable [7]. The review concluded that therapeutic
exercise, especially with specialised hand-on exercise
training and an element of strengthening, is an effica-
cious treatment for hip OA.
There is evidence from a high quality randomised con-
trolled trial that manual therapy may be more effective
than exercise in hip OA [8]. A 5-week manual therapy
program comprising mobilisation and manipulation of
the hip joint was compared to a therapist-supervised
exercise program in 109 patients with hip OA [8]. Both
groups showed improvement but the success rate in the
manual therapy group (81%) was significantly better than
that in the exercise group (50%). Benefits in favour of
manual therapy were maintained at a 29-week follow-up.
Physiotherapy treatment can comprise a number of
components including exercise, manual therapy, educa-
tion and advice, and the prescription of gait aids. In
practice most or all of these components, tailored to the
individual patient’s particular presenting musculoskeletal
impairments, are provided within physiotherapy treat-
ment programs. While several studies and reviews have
evaluated individual components of conservative treat-
ments, none has evaluated a multimodal approach typi-
cal of physiotherapy treatment for hip OA. Given the
limited research in the area, this project primarily aims
to investigate the efficacy of a 12-week multimodal phy-
siotherapy program to treat pain and physical dysfunc-
tion in individuals with hip OA. Secondary aims are to
assess changes in relevant musculoskeletal impairments
with treatment, maintenance of treatment effects over 6
months and the cost-effectiveness of physiotherapy.
Primary hypothesis
H1: A 12-week multimodal, individualised physiotherapy
program will result in significantly greater improve-
ments in pain and physical function than sham phy-
siotherapy immediately post-treatment in individuals
with hip OA.
Secondary hypotheses
H2: A physiotherapy program will result in significantly
better participant-perceived response to treatment and
greater improvements in health-related quality of life,
functional performance, gait biomechanics and
musculoskeletal impairments than sham physiotherapy
immediately post treatment.
H3: Symptomatic improvements following a 12-week
physiotherapy program will be sustained at a 6-month
follow-up with a home exercise program.
H4: A physiotherapy program will be more cost-effec-
tive than sham physiotherapy when hip OA-related
costs are compared and related to the effects of the
active intervention.
This paper provides the rationale and background to
the study and outlines the design and analysis plan.
Methods
Trial design
This is a randomised, assessor- and participant-blinded,
placebo controlled trial of a 12-week physiotherapy pro-
gram with a 6-month follow-up. Measurements will be
taken at baseline, 13 weeks and 36 weeks. The protocol
conforms to CONSORT guidelines for non-pharmacolo-
gical interventions [9] and the protocol is designed to
conform to the principles of the Declaration of Helsinki.
Participants
We will recruit 128 people from the community in the
Melbourne metropolitan region via advertisements in
local clubs, libraries, print and radio media, and Face-
book, and from medical practitioners (orthopaedic sur-
geons, rheumatologists and general practitioners). We
will also use our database of people who were recruited
from the community for prior studies and have given
consent for future contact.
To be eligible, participants must have:
(i) hip OA fulfilling American College of Rheumatol-
ogy classification criteria [10] with pain in the groin
or hip region on most days of the past month and
femoral or acetabular osteophytes and joint space
narrowing (superior, axial and/or medial) ≥ Grade 2
on a standing x-ray;
(ii) overall average hip/groin pain in the last week ≥
40 on 100 mm visual analogue scale (VAS) (to
ensure a minimal level of pain);
(iii) pain in the groin or hip region for more than 3
months;
(iv) moderate level of interference in activities of
daily living;
(v) aged ≥ 50 years.
The exclusion criteria are:
(i) hip surgery within past 6 months;
(ii) awaiting or planning any back or lower limb sur-
gery in the next 9 months;
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articular corticosteroid use;
(iv) systemic arthritic conditions such as rheumatoid
arthritis;
(v) history of hip or knee joint replacement or
osteotomy on the test leg;
(vi) other previous hip pathology such as fracture or
cancer on the test leg;
(vii) other muscular, joint or neurological condition
causing pain or affecting lower limb function;
(viii) physiotherapy, chiropractic treatment or exer-
cises specifically for the hip or lumbar spine in past
6 months;
(ix) any medical or physical impairment apart from
hip OA precluding safe participation in exercise or
manual therapy such as uncontrolled hypertension,
or morbid obesity (body mass index > 40);
(x) walking continuously for more than 30 minutes
daily or participating in exercise more than once a
week;
(xi) inability to walk unaided;
(xii) unable to comply with protocol;
(xiii) inadequate written and spoken English.
Procedure
The procedure is outlined in Figure 1. Preliminary
screening will be conducted over the telephone. A stan-
dardised anteroposterior pelvic x-ray will be obtained in
a standing position with 15° internal foot rotation [11]
at one of three trial radiology centres, unless they can
provide their own films from a weight-bearing x-ray
within the previous 12 months. X-rays will be used to
determine eligibility and to grade OA severity. X-ray
grading will be performed by two trained researchers
and any disagreement will be resolved through discus-
sion or where necessary, a third rater. Potential partici-
pants will then attend the Department of Physiotherapy,
University of Melbourne for physical screening by a
physiotherapist to ensure that the reported symptoms
are arising from the hip and not from the lumbar spine.
We will maintain a screening record to document the
criteria eliminating those found to be ineligible. Follow-
ing baseline testing, the participant will be randomised
into one of two groups: (i) active physiotherapy or (ii)
sham physiotherapy. Participants will be reassessed after
the 12-week intervention (week 13) and again six
months later (week 36). During the 6 month follow-up
period, participants in the active physiotherapy group
will be requested to continue with an unsupervised
home exercise program while those in the sham phy-
siotherapy group will be asked to gently apply non-ther-
apeutic gel to their hip region at home. Participants will
be asked to refrain from seeking other treatments
during the trial but analgesia and anti-inflammatory
drugs will be permitted. All medication use and co-
interventions will be recorded.
Ethical approval has been obtained from the Univer-
sity of Melbourne Human Research Ethics Committee
(HREC #0932812) and Radiation Safety Human Services.
All participants will provide written informed consent.
Randomisation and allocation concealment
The randomisation schedule will be prepared by the
study biostatistician (AF) using a computer generated
random numbers table. Randomisation will be by ran-
dom permuted blocks stratified according to therapist
(to control for therapist variation). To conceal randomi-
sation, consecutively numbered, sealed, opaque envel-
opes will be used and maintained centrally. An
independent staff member will prepare the envelopes.
These will be kept in a locked location accessible only
by a research administrator. An envelope will be opened
in sequence once the participant has completed all base-
line measurements. Allocation will be revealed to the
treating physiotherapist by fax/email prior to the partici-
pant presenting for treatment.
Blinding
The outcome assessor (BM) will be blind to group allo-
cation and will not be involved in providing the inter-
ventions nor will s/he visit any of the treatment centres.
The plain language statement will inform participants
that they have an equal chance of receiving active or
sham physiotherapy but it will not provide any details of
the actual treatments. To assist with blinding, partici-
pants in different groups will not attend treatment ses-
sions concurrently. Participants will be requested not to
disclose details about their treatment with the outcome
assessor. The physiotherapists delivering the interven-
tions cannot be blinded. The statistician(s) performing
the statistical analyses will be blind to group allocation
until completion of the analyses.
Interventions
Participants in both groups will attend 10 individual
treatment sessions with a physiotherapist over 12 weeks
(Table 1). The timing of the sessions will be twice in the
first week then weekly until week 7, then two weeks
apart for the final two appointments. The first two treat-
ment sessions will last for 45-60 minutes to allow for a
more detailed subjective and objective assessment, after
which all sessions will be 30 minutes in duration. This
reflects a realistic treatment dosage in clinical practice.
Eight experienced Project Physiotherapists (at least 5
years of relevant clinical experience and with postgradu-
ate qualifications in manipulative or musculoskeletal
physiotherapy) located at private practices in
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Page 4 of 13metropolitan Melbourne will be trained to deliver both
the active and sham treatments. The training involves a
2-day training course delivered by experienced clinician
researchers (JHA, KS and KB) together with a detailed
100-page treatment manual and a DVD showing the
techniques and exercises. Having a number of treating
physiotherapists is necessary for practical reasons and to
improve the generalisability of results. To ensure that
factors such as therapist personality and style, which
may influence outcome, are evenly distributed between
treatment groups, each therapist will treat similar pro-
portions of active and sham participants. At the end of
each treatment session, the therapist will complete a
‘Treatment Notes’ form to record the interventions
administered.
The integrity of the interventions will be ensured by a
variety of methods. Therapist adherence to the protocol
will be ensured by holding training sessions and regular
therapist team meetings, providing a comprehensive
treatment manual and DVD, having structured record-
ing forms, auditing the recording forms, observing treat-
ment sessions and interviewing participants. To evaluate
the credibility of both interventions, the Treatment
Credibility Scale [12] will be administered by the thera-
pists to participants after the first and last physiotherapy
treatment sessions.
Active physiotherapy
The active physiotherapy program is semi-structured
comprising core components plus optional additional
treatment components. The therapist is able to choose
the most appropriate combination and level of manual
therapy techniques and exercises from a limited, pre-
specified range. Initial selections are based on a standar-
dised clinical assessment performed in the first session.
The clinical assessment includes subjective and objective
components following which the physiotherapist will
generate a problem list and identify the musculoskeletal
impairments to be the treatment priorities. The objec-
tive assessment includes functional movements, passive
range of motion and muscle length tests, muscle
strength tests and lumbar-pelvic control tests. A brief
subjective and objective assessment will also be per-
formed at the start of each subsequent treatment ses-
sion to gauge response to treatment, re-identify
treatment priorities and alter selection of techniques
and exercises.
The four treatment components are (Table 2):
(i) Manual therapy techniques applied by the therapist
and designed to improve the quality and range of
motion of the hip and surrounding soft tissues and to
reduce pain.
(ii) Home exercises and 10 minutes cycling on a sta-
tionary exercise bike at the end of each physiotherapy
treatment session.
(iii) Education and advice covering issues such as what
is OA, why does it occur, how it is treated, what are the
benefits of exercise, the importance of increasing overall
physical activity levels in everyday life and how to pro-
tect the joint during activities such as sitting, walking,
stair climbing, standing, load-carrying and sleeping.
Table 1 Overview of Active Physiotherapy and Sham Physiotherapy Treatments. The times given are approximate
Active Physiotherapy Overview Sham Physiotherapy Overview
Session 1 (45-60 mins)
￿ Subjective and objective assessment (20-25 mins)
￿ Patient education (5 mins)
￿ 2 of the mandatory manual therapy techniques (5-10 mins)
￿ Teach hip abduction and knee extension strengthening home exercises (15-20 mins)
Session 1 (45-60 mins)
￿ Subjective and objective assessment (20-25 mins)
￿ Patient education (5 mins)
￿ Information about gel and application (5-10 mins)
￿ Information about pulsed ultrasound and
application (10 mins)
￿ Discuss log-book and attendance (5-10 mins)
Session 2 (45-60 mins)
￿ Subjective and objective re-assessment (10 mins)
￿ Patient education (5-10 mins)
￿ 2-4 of the mandatory manual therapy techniques (15-20 mins)
￿ Teach all mandatory home exercises and check log-book (15-20 mins)
Session 2 (45-60 mins)
￿ Subjective and objective re-assessment (23 mins)
￿ Application of sham gel (10-15 mins)
￿ Application of sham pulsed ultrasound (10-15 mins)
￿ Check and discuss log-book (2-7 mins)
Session 3-10 (30 mins)
￿ Subjective and objective re-assessment (5 mins)
￿ All mandatory manual therapy techniques with addition of optional techniques if justified
(15 mins)
￿ Progress all mandatory home exercises, addition of optional exercises if justified and check
log-book (10 mins)
Session 3-10 (30 mins)
￿ Subjective and objective re-assessment (13 mins)
￿ Application of sham gel (7 mins)
￿ Application of sham pulsed ultrasound (8 mins)
￿Check log-book (2 mins)
Follow-up period
￿ 5 home exercises 3 times/week
Follow-up period
￿ Self-application of gel 3 times/week
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Manual Therapy Techniques Description Dosage
Mandatory techniques:
Long axis distraction with thrust Supine. The hip is in 15-30° flexion, 15-30 ° AB, slight ER.
Preferably use seat belt. Perform 3-6 thrusts at the beginning
of the first set then perform oscillations in the remaining sets.
3-6 sets of 30 secs
Seatbelt glide, or distraction mobilisations, with the hip flexed Supine with hip flexed and using a seatbelt, oscillatory passive
accessory mobilisation forces applied caudally or laterally to
the proximal thigh.
3-6 sets of 30 secs
Internal rotation in prone Prone with knee flexed. IR until contralateral pelvis rises, apply
oscillatory force downwards to contralateral pelvis.
3-6 sets of 30 secs
Soft-tissue or deep-tissue massage of quads, adductors,
hamstrings, psoas, lateral hip muscles and/or posterior hip
muscles and associated fascia
Firm effleurage stroke, deep frictions or sustained pressure
trigger point release with the muscle on stretch.
2-5 mins
Optional techniques:
Long axis distraction in prone Prone. The hip is in 10-15 ° AB. Preferably use seat belt.
Perform caudally directed oscillations. May perform 3-6 thrusts
at the beginning of the first set.
3-6 sets of 30 secs
Antero-posterior progression (posterior glide) Supine with hip in flexion and adduction. Use body weight to
impart passive oscillations to the postero-lateral hip capsule
through the long axis of the femur. Add more flexion,
adduction, &/or internal rotation to progress.
3-6 sets of 30 secs
Postero-anterior progression (anterior glide) Prone with knee bent. Leg supported at knee (may use
seatbelt). Pressure applied inferior and medial to greater
trochanter in posterior to anterior direction. Vary amount of
hip flexion/extension, AB/AD, IR/ER. Modify to use figure-4
position and apply pressure through sacrum.
3-6 sets of 30 secs
Manual stretches to one joint knee extensors, rectus femoris,
hip flexors, hamstrings, hip internal rotators, hip external
rotators, or hip adductors
Stretch should be felt in target muscle. Manual stretches
should match the soft or deep tissue massage technique
selected.
6 reps × 20 secs or
4 × 30 secs or 2 ×
60 secs
Lumbar spine mobilisation –Unilateral postero-anterior accessory glides
–Passive physiological lumbar spine rotation
–Lumbar spine manipulation (supine)
–Lumbar spine manipulation (side lying with affected hip
up)
3-6 sets of 30 secs
Home exercises Description Dosage
Mandatory techniques: [Exercise difficulty must be progressed]
Hip abductor strengthening Progressed through supine, standing, side lying and standing
wall press.
3 × 10 repetitions
Quads strengthening exercise Progressed through sitting elastic band press or knee
extension, partial squats, partial wall squats*, sit-to stand* and
split sit to stand.
3 × 10 repetitions
Muscle stretch (should match with the soft tissue/deep tissue
massage technique chosen in the manual therapy section
– Hip extension
–Hip flextion
–Hip abduction and external rotation
–Hip internal rotation
2 mins total with
20-60 sec hold
times
Challenging functional neuromuscular balance/gait drills set –standing weight shifting forwards
#, lateral
# and tandem
stance
#
–standing hip control progressing to eccentric hip
abductor exercise
–balance in double leg stance on foam
# or single leg
stance
#
–side stepping progressing to ‘carioca’ (or braiding)
–shuttle walking
–stairs
1-2 exercises (4
minutes total time)
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used in the contralateral hand if deemed necessary by
the therapist to improve gait pattern and reduce pain
response to walking.
The participant will perform the prescribed home
exercises four times weekly, for which weights and resis-
tance elastic bands will be provided as well as hand-outs
describing the exercises. To assist with adherence, the
number of home exercises is limited to between four
and six [13]. A log-book will be completed by partici-
pants to record adherence to the home exercises during
the treatment period.
Sham physiotherapy
As for many procedural interventions, it is difficult to
design a placebo treatment that completely mimics a
physiotherapy program. However, our aim is to control
for attention and time with a therapist and the belief
that treatment will assist hip OA. Participants in the
sham physiotherapy group will receive the same num-
ber and length of visits as those in the active phy-
siotherapy group but will receive only inactive
ultrasound and gentle application of a non-therapeutic
gel. These emulate common physiotherapy modalities
and thus represent realistic placebo options. Partici-
pants in the sham group will receive no instruction in
exercise techniques and no manual therapy. We have
used this identical sham protocol in four randomised
controlled trials of physiotherapy for patellofemoral
pain [14], knee OA [15], chronic shoulder pain [16]
and frozen shoulder [17] involving more than 580 par-
ticipants. On average 50%-70% of those in the sham
group thought they received ‘real’ treatment or were
unsure, and formal statistical analysis showed that
blinding was successful. Furthermore, a similar sham
protocol was used as a control for exercise in a low
back pain trial and participants rated the credibility of
this sham treatment highly [18]. This indicates that
this sham treatment provides acceptable blinding in a
trial of this nature.
Follow-up period
During the 6 month follow-up period, participants in
the active physiotherapy group will perform an unsu-
pervised home exercise program prescribed by their
physiotherapist at their final treatment session. The
program will comprise five exercises performed three
times per week. Participants in the sham physiother-
apy group will gently apply the non-therapeutic gel to
their hip region for five minutes, three times per
week.
Outcome measures
Outcome measures have been selected based on those
recommended for clinical trials of OA [19,20]. In those
with bilateral hip OA, only the most symptomatic hip
will be assessed.
Table 2: Details of the Physiotherapy Treatment (Continued)
Optional techniques: [Maximum of two]
Strengthening exercise(s) –hip extensors progressed through gluteal sets, bridging*
and unilateral bridging
–hip external rotators progressed through clamshells (or
sitting or 4-point kneeling internal rotation), resisted
clamshells (or sitting internal rotation) and standing wall
press
–hip internal rotators progressed through 4-point kneeling,
sitting and bottom-leg clamshells
3 × 10 repetitions
Additional stretches(s) (as above)
Lumbopelvic control exercise Supine pelvic tilt with progressions 10 repetitions
* Option to add elastic band resistance around both knees.
# Option to close eyes.
Patient education
–About osteoarthritis
–Response to exercise and daily physical activity
–Activity-rest cycle versus over-activity cycle
–Joint protection advice
Prescription of a single walking stick Only if it will enable the patient to improve their gait pattern and increase their daily
physical activity.
Stationary cycling Up to 10 minutes at a moderate level of intensity (rated as “hard” up to “very hard”
–level 5-8 on the Modified Borg Rating Scale of Perceived Exertion achieved within 2
minutes of activity if possible) after each treatment session while at the
physiotherapy clinic.
The treatment program was structured to include a number of mandatory components plus some optional components. Individual technique selection was
guided by assessment findings and radiological presentation.
AB = abduction, AD = adduction, ER = external rotation, IR = internal rotation.
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Page 7 of 13Age, gender, duration of hip OA symptoms, previous
treatment, surgery and medication use for hip OA,
employment status, marital status, education level and
previous health problems will be obtained by question-
naire. Radiographic disease severity will be assessed
from the baseline x-ray using the Kellgren and Lawrence
grading system [21] while individual features of osteo-
phytes and joint space narrowing will be rated using the
Osteoarthritis Research Society International Grading
system [22].
Primary outcome measures
The primary outcomes will be change in pain and
change in self-reported physical function at 13 weeks
(Table 3). Overall average hip pain in the past week will
be self-assessed by a 100 mm VAS with terminal
descriptors of ‘no pain’ and ‘worst pain possible’.S u c h
measurement has demonstrated reliability in OA [19].
Physical function will be self-assessed using the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) Likert version 3.1. This is a disease-specific
instrument whose validity, reliability and responsiveness
have been demonstrated in an extensive range of OA
studies [23]. The physical function subscale has 17 items
with a five point Likert response giving a total score out
of 68.
Secondary outcome measures
A number of secondary measures will be included
(Table 3). The Hip Osteoarthritis Outcome Scale
(HOOS) is a patient-administered measure that assesses
the patient’s opinion of their hip and associated pro-
blems over the previous week. It consists of five sub-
scales; pain, other symptoms, function in daily living,
function in sport and recreation, and hip-related quality
of life. A normalised score (100 indicating no symptoms
and 0 indicating extreme symptoms) is calculated for
each subscale [24].
A number of functional performance tests and muscu-
loskeletal impairments will be measured at baseline and
at 13 weeks. The passive range of hip flexion, extension,
abduction, internal rotation and external rotation will be
measured using clinical methods and an inclinometer.
The test retest reliability ICCs for these measures ran-
ged from 0.82 to 0.94 in 25 patients with hip OA tested
one week apart [25]. For all measures, two trials will be
performed and the mean reading used in analysis. Hip
flexion, extension and abduction will be measured in
supine while internal and external rotation will be mea-
sured in sitting
An instrumented manual muscle tester will be used to
measure maximum, normalised isometric strength (peak
torque; Nm/kg) of the hip abductor, extensor, flexor and
internal and external rotator muscles. Our reliability
ICCs ranged from 0.65 to 0.85 in six patients with hip
OA tested a week apart [25]. Measurements of hip
abductors and extensors will be taken in supine while
those of the flexor and rotator muscles will be taken in
sitting. Maximum voluntary isometric torque of the
quadriceps and hamstring muscles at 60° knee flexion
will be measured in sitting using a KinCom isokinetic
dynamometer (reliability ICCs were 0.85 for quadriceps
and 0.85 for hamstrings for ten patients with painful hip
OA). Testing will comprise two maximal contractions
with the peak value used for analysis.
Several functional tests will be included. The stair
climb test [26] involves timing how long it takes partici-
pants to ascend and descend six steps at their own pace.
For the 30 second sit-to-stand test, the number of times
participants can rise to a full standing position from sit-
ting and return to sitting in 30 seconds is counted [27].
Walking performance will be assessed by calculating
walking velocity (m/sec) as participants walk 20 meters
with the instructions ‘walk as quickly as you can without
overexerting yourself’ [28]. Dynamic standing balance
will be assessed by the step test [29] and the 4-square
step test [30].
In a subset of participants, gait analysis will be per-
formed at baseline and at 13 weeks. Kinematic and
ground reaction force data will be recorded simulta-
neously for five walking trials in usual footwear at self-
selected pace using a 3-D motion analysis system with12
cameras (Vicon MX, Oxford, UK) and three force plates
(AMTI, Massachusetts, USA) concealed in the floor.
Kinematics will be derived from the standard Davis-
Kadaba marker set using Vicon Plug-in Gait model.
Data will be combined using inverse dynamics to yield
measures of external joint moments. The main measures
will be peak external hip adduction and abduction
moments, peak external hip flexion and extension
moments, pelvic drop/rise in the frontal plane and pel-
vic rotation ranges of motion, and peak and total range
of hip motion in the sagittal and transverse planes.
Reliability in our laboratory is good for the measures we
have subjected to reliability testing, with ICCs of 0.56 to
0.95 (the majority > 0.80) from six patients with hip OA
and six controls tested twice one week apart.
T h eA s s e s s m e n to fQ u a l i t yo fL i f ei n s t r u m e n tv e r s i o n
2 (AQoL II) has 20 questions that cover six dimensions
of health-related quality of life including independent
living, social relationships, physical senses, coping, pain
and psychological wellbeing. The AQoL has strong psy-
chometric properties and is more responsive than other
widely-used scales [31,32]. It produces a single utility
index that ranges from -0.04 (worst possible health-
related quality of life) to 1.00 (full health-related quality
of life). A clinically important difference in health-
related quality of life can be defined as a change of 0.04
AQoL units [33]. The AQoL will be collected at weeks
0, 13, and 36.
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ways, using a questionnaire and using a pedometer. The
Physical Activity Scale for the Elderly (PASE) will be
used to measure both the level and type of recreational
and occupational physical activity undertaken by partici-
pants over the previous week. The PASE was developed
and validated in samples of older adults (age 55+ years)
[34]. A pedometer (HJ-005 Omron Healthcare, Japan)
will be worn for a week on three occasions (baseline, 13
weeks and 36 weeks) to record the number of steps
taken per day. Participants will be asked to wear the
pedometer full time during their waking hours. Ped-
ometers have been found to be a simple and inexpensive
means to estimate physical activity levels [35,36]. It is
recommended that at least three days of sampling are
needed to accurately assess activity levels given differ-
ences between weekends and weekdays [37].
The Arthritis Self Efficacy Scale will be used to mea-
sure psychological status. It has three subscales that
assess self-efficacy for control of pain management, phy-
sical function and other arthritis symptoms. Prior stu-
dies have supported both the reliability and validity of
this scale [38]. Pain catastrophizing will be measured
using the 13-item Pain Catastrophizing Scale. It mea-
sures tendencies to ruminate about pain, magnify pain,
and feel helpless about pain. It has high internal consis-
tency (coefficient alpha = .87) and is associated with
heightened pain, psychological distress, and physical dis-
ability [39]. We will use the Coping Attempts Scale of
the Coping Strategies Questionnaire to assess the use of
pain coping skills [40]. This 42-item scale measures how
often a patient engages in 7 different pain coping strate-
gies. This instrument has demonstrated sensitivity to
change from treatment in chronic pain samples as well
as good internal consistency and construct validity [41].
Participants will rate their perceived overall change
and their change specifically in pain and in physical
function with treatment (compared to baseline) on
seven-point ordinal scales (1-much worse to 7-much
better). Scales of this kind are frequently used as an
external criterion for comparison with changes in scores
of other outcomes [42]. Measuring patient perceived
change using a rating of change scale has been shown
to be a clinically relevant and stable concept for
Table 3 Summary of measures to be collected
Primary outcome measures Data collection instrument Collection
points
Average pain in past week 100 mm VAS 0, 13, 36 weeks
Physical function in past 48 hours WOMAC Osteoarthritis Index 3.1 Likert version 0, 13, 36 weeks
Secondary outcome measures
Pain, function, and stiffness HOOS (incorporating WOMAC) 0, 13, 36 weeks
Health-related quality of life Assessment of Quality of Life Instrument version 2 (AQoL II) 0, 13, 36 weeks
Patient’s global rating of change overall
and for pain and function
7-point ordinal scale 13, 36 weeks
Self efficacy Arthritis Self-efficacy scale 0, 13, 36 weeks
Pain catastrophizing Pain Catastrophizing Scale 0, 13, 36 weeks
Coping strategies Coping Strategies questionnaire 0, 13, 36 weeks
Objective functional performance Timed 40 m walk
Timed stair climb (ascent and descent)
30 second sit-to-stand
0, 13 weeks
Standing balance Step test
4-square step test
0, 13 weeks
Hip range of motion Clinical methods and inclinometer 0, 13 weeks
Hip and knee muscle strength Isometric - isokinetic dynamometer (quadriceps and hamstrings) and instrumented
manual muscle tester (hip flexors, extensors, abductors, rotators)
0, 13 weeks
Gait biomechanics (in a subset) 3-dimensional motion analysis system 0, 13 weeks
Other measures
Physical activity levels Physical Activity Scale for the Elderly (PASE)
Pedometer worn for 7 days
0, 13, 36 weeks
Treatment credibility Treatment Credibility Scale 1,12 weeks
Participant success of blinding Questionnaire 13, 36 weeks
Healthcare consumption and related costs Questionnaire; health system records 0, 5, 9, 13, 36
weeks
Adverse events Participant log-book Throughout
Adherence - treatment session attendance;
home exercise or gel application
Participant log-book; Therapist treatment records; Questionnaire Throughout
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individual perspective [43]. We will also dichotomise the
group according to their perceived change rating where
improved will be defined as ‘moderately’ or ‘much’ bet-
ter, and not improved will be defined as ‘slightly’ better
and below. The proportion of improved participants
from each group will determine success of the
treatment.
Other measures
A number of other measures will be obtained (Table 3).
Participant adherence will be obtained by recording the
number of physiotherapy sessions attended (out of a maxi-
mum number of ten). Those in the active physiotherapy
group will complete a daily log-book to record the number
of home exercise sessions completed during the treatment
phase. To indicate adherence to the home program during
the six-month follow-up period, participants in both
groups will be mailed a short questionnaire at Weeks 24
and 36 which asks how many times in the past week they
have performed the home exercises or applied the gel.
Adverse events and the use of co-intervention will be
recorded in a log-book and by open-probe questioning by
the assessor at trial completion. At the 13 week and 36
week measurement time points, study participants will be
asked to indicate which treatment they believe they have
received (active or sham) and reasons for that choice to
assess the success of blinding.
Information on health care costs and direct non-
health care costs over the last month will be collected
retrospectively at week 0, 5, 9, 13, and 36 by question-
naire. Direct health care costs will include costs of phy-
siotherapy attendance (assumed zero in the sham
group), additional health provider visits (doctors, specia-
lists, other health care professionals), investigative pro-
cedures, purchase of prescription and over the counter
medication, and hospitalisation. These will be valued
using published prices for medical costs. Direct non-
health care resources will include number of lost days
from work.
The monetary valuation of health status pre- and
post-treatment is potentially a more comprehensive
patient relevant measure of treatment gains than mea-
sures of either a clinical outcome or health-related qual-
ity of life. A simple open-ended questionnaire will ask
participants in each group about their willingness to pay
for the treatment given the outcomes they experience.
Sample size
Our two primary endpoints are hip pain measured on a
VAS and WOMAC physical function score. The mini-
mum clinically important difference to be detected in
OA trials is a change in pain of 18 mm (on 100 mm
VAS) [44] and a change of six physical function
WOMAC units (out of 68) [45]. Based on our previous
data, we assume a common between-subject standard
d e v i a t i o no fc h a n g eo f3 0m mf o rp a i nV A Sa n d1 2
units for WOMAC physical function as well as a base-
line to 13 weeks correlation in scores of 0.6. These sta-
tistics indicate a smaller standardised effect size of
interest (Cohen’s d)o f0 . 5f o rt h eW O M A Cm e a s u r e
than the d of 0.6 for pain. The required sample for an
analysis of covariance of change in scores controlling for
the baseline value of the variable when d is 0.5, power is
0.9 and type I error is set at .05 is 54 participants per
group. In addition, at 54 participants per group the
power will be even greater for pain. Allowing for an
approximate 15% drop-out rate, we will recruit 64 parti-
cipants per group.
Data and statistical analysis
The primary analysis of the data will be undertaken
using the principle of intention-to-treat (ITT). Our ITT
analysis will include all participants including those who
have missing data and those who are not fully compliant
with the protocol. Some attrition is anticipated despite
the fact that we will implement procedures to minimise
loss to follow-up and participant withdrawal, and maxi-
mise adherence. Multiple imputation methodology will
be employed to account for missing data [46].
Demographic and clinical characteristics as well as
baseline data will be presented to assess the baseline
comparability of the intervention groups. These vari-
ables will also be examined for those participants who
withdraw from the study and those who remain.
Descriptive statistics will be presented for each group
as the mean change (standard deviation, 95% confidence
intervals) in the outcomes from baseline to each time
point. Differences in mean change from baseline to each
time point will be compared between groups using gen-
eralised linear regression modelling adjusting for base-
line levels of the outcome measure. Model assumptions
will be checked by standard diagnostic plots.
Improvement between active and sham physiotherapy
groups based on the perceived ratings of change will be
compared using log binomial regression and presented
as relative risks with 95% confidence intervals.
As part of the secondary analyses of the primary out-
comes at 13 and 36 weeks, we plan to conduct a sepa-
rate analysis to estimate the effect of treatment in the
hypothetical scenario of full adherence to randomised
treatment modality. Adherence will be defined as atten-
dance at more than 80% of scheduled treatment sessions
and 60% of prescribed home exercise sessions in the
active physiotherapy group. This is based on definitions
used in another study of manual therapy and exercise in
hip OA [47]. Analytical methods for this will utilise
instrumental variables methodology involving two stage
least squares estimation [48].
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assess the success of participant blinding will be com-
puted [49].
No statistical adjustment will be made for multiple
testing. All tests will be two sided and carried out at the
5% level of significance. Any changes to the study design
or analysis plan will be documented with full
justification.
Economic evaluation
The economic evaluation will be conducted from the
perspective of the Australian health care system and the
individual patient. The primary economic evaluation will
take the form of a cost effectiveness study of the cost
per extra quality adjusted life years (QALYs). QALYs
will be calculated using the AQoL scores over 36 weeks.
Differences in mean change from baseline for the AQoL
to each time point will be weighted by the time from
baseline using generalised linear regression modelling
adjusting for baseline levels of the AQoL to construct
QALYs, and then compared between groups. Differences
in the mean cost between groups will be calculated
using generalised linear regression modelling. Incremen-
tal cost per QALY will be calculated as the ratio of the
difference in mean cost to the difference in mean
QALYs with 95% confidence intervals calculated using
Fieller’s theorem. As supplementary analyses the incre-
mental cost per extra person with a clinically significant
improvement in function, and per extra person per-
ceived to be recovered will be calculated
Timelines
Ethics approval was obtained from the Human Research
Ethics Committee of the University of Melbourne in April
2010. Recruitment and training of the physiotherapists
was undertaken in April 2010 and recruitment of partici-
pants has commenced. All participants are expected to
have completed the study by September 2012.
Discussion
There are several major strengths of the intervention
design in this study. Firstly, the multimodal nature of
the active physiotherapy program mimics contemporary
physiotherapy clinical practice in Australia and many
other countries. Patients are treated with a combination
of manual therapy techniques and complementary exer-
cises. Given that both exercise and manual therapy
alone have been shown to be effective for symptomatic
relief in hip OA [8], we contend that the multimodal
nature of our program is likely to be more efficacious
than either intervention alone.
Secondly, patients’ treatment programs are individua-
lised using a problem-solving approach following assess-
ment of musculoskeletal impairments. This allows the
program to target the presenting musculoskeletal
impairments that contribute the patients’ symptoms and
functional limitations. It also aligns with theg u i d e l i n e s
from EULAR, which recommend tailored treatment [4].
The semi-structured nature of the program, where there
are constraints on the number and options for manual
therapy techniques and exercises from which the phy-
siotherapists can choose, will reduce treatment variation
and allow the delivered treatments to be more easily
reported and replicated. Finally, the delivery of the inter-
ventions by multiple practicing community physiothera-
pists will improve the generalisability of the findings.
We considered it important to control for non-specific
treatment effects (often referred to as placebo effects) in
the study design, given the role these play in influencing
treatment outcome. A recent meta-analysis showed that
for active treatment of chronic pain conditions (not spe-
cifically hip OA), spontaneous recovery contributes
around 10% and placebo effects around 30% [50]. Pla-
cebo effects have also been found to be greatest for
non-pharmacological interventions and for patient-
reported outcomes particularly pain [51]. In fact, the
sham physiotherapy treatment that we will utilise was
associated with a 38% reduction in pain in our previous
study in patients with knee OA [15]. While we acknowl-
edge that such indirect treatment effects are an impor-
tant component of a physiotherapy treatment, we wish
to evaluate the additional benefit of direct treatment
that target identified musculoskeletal impairments. We
did not include a ‘no treatment’ option as a third study
arm as natural recovery is unlikely to occur in these
participants who have at least a mild degree of radio-
graphic joint change and report functional disability at
baseline.
Our outcome measures are those recommended for
use in clinical trials of OA [20]. These include self-
report measures of pain, function, quality of life and glo-
bal response to treatment. A range of other measures
are included to also incorporate functional performance,
strength, range of motion, psychological aspects, gait
biomechanics and physical activity levels in our investi-
gation. We have specified two primary outcomes with
the other measures being either secondary outcomes or
mechanistic measures which will help us understand the
underlying mechanisms explaining changes in pain and
function. A health economics assessment is included
given the need to justify the cost-effectiveness of treat-
ments in the current economic climate.
Conclusions
This study uses a randomised controlled trial design to
investigate whether a multimodal individualised phy-
siotherapy program that incorporates manual therapy
a n de x e r c i s ei sm o r ee f f i c a c i o u sa n dc o s t - e f f e c t i v ef o r
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Page 11 of 13the management of symptoms in people with hip OA
than a sham physiotherapy treatment that controls for
therapist attention. The study design leads to some lim-
itations of generalisability due to a number of inclusion/
exclusion criteria, however the design has major
strengths related to reproducibility and reflecting con-
temporary clinical practice. The findings will enable evi-
dence-based recommendations as to the usefulness of
this conservative option for the management of patients
with hip OA.
Acknowledgements
This trial is being funded by the National Health and Medical Research
Council (Project #628556). None of the funders have any role in the study
other than to provide funding. KLB is funded in part by an Australian
Research Council Future Fellowship. RB is funded in part by an Australian
National Health and Medical Research Council Practitioner Fellowship.
The Project Physiotherapists providing the active and sham physiotherapy
treatments are David Bergin, Sallie Cowan, Andrew Dalwood, Laurie
McCormack, Ian McFarland, Geoff Pryde, Darren Ross and Paul Visentini.
Author details
1Centre for Health, Exercise & Sports Medicine, School of Health Sciences,
University of Melbourne, Melbourne, VIC, Australia.
2Department of
Physiotherapy, Singapore General Hospital, Singapore.
3Dunedin School of
Medicine, University of Otago, Dunedin, New Zealand.
4Cricket Australia
Centre of Excellence, Brisbane, Australia.
5Department of Epidemiology and
Preventive Medicine, School of Public Health and Preventive Medicine,
Monash University, Melbourne, VIC, Australia.
6Centre for Health Economics,
Monash University, Melbourne, VIC, Australia.
7Monash Department of
Clinical Epidemiology, Cabrini Hospital, Melbourne, VIC, Australia.
Authors’ contributions
KLB conceived the project and is leading the co-ordination of the trial. KLB,
RB, TW, YHP, AF and AH assisted with protocol design and procured the
project funding. KLB, RB and TE wrote this manuscript. AF designed the
statistical analysis and provided the randomisation schedule. AH designed
the economic evaluation. TW and YHP designed the biomechanical and
physical impairment measures. KLB, JHA, KS and YHP designed the active
physiotherapy intervention and JHA, KS and KLB trained the therapists. TE
wrote the protocol manual and the final drafts of this manuscript. BM is the
blinded assessor on the project while FM recruits and screens the
participants. All authors participated in the trial design, provided feedback
on drafts of this paper and read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 September 2010 Accepted: 14 October 2010
Published: 14 October 2010
References
1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA,
Gabriel S, Hirsch R, Hochberg MC, Hunder GG, et al: Estimates of the
prevalence of arthritis and other rheumatic conditions in the United
States. Part II. Arthritis & Rheumatism 2008, 58(1):26-35.
2. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N,
Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, et al: OARSI
recommendations for the management of hip and knee osteoarthritis,
Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis
& Cartilage 2008, 16(2):137.
3. Conaghan PG, Dickson J, Grant RL: Care and management of
osteoarthritis in adults: summary of NICE guidance. BMJ 2008,
336(7642):502-503.
4. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP,
Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, et al: EULAR
evidence based recommendations for the management of hip
osteoarthritis: report of a task force of the EULAR Standing Committee
for International Clinical Studies Including Therapeutics (ESCISIT). Ann
Rheum Dis 2005, 64(5):669-681.
5. Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S: Exercise for
osteoarthritis of the hip. Cochrane Database of Systematic Reviews 2009, 3.
6. McNair PJ, Simmonds MA, Boocock MG, Larmer PJ: Exercise therapy for
the management of osteoarthritis of the hip joint: a systematic review.
Arthritis Res Ther 2009, 11(3):R98.
7. Hernandez-molina G, Reichenbach S, Zhang B, Lavalley M, Felson D: Effect
of therapeutic exercise for hip osteoarthritis pain: results of a meta-
analysis. Arthritis Care and Research 2008, 59:1221-1228.
8. Hoeksma H, Dekker J, Ronday H, Heering A, van der Lubbe N, Vel C,
Breedveld F, van den Ende C: Comparison of manual therapy and
exercise therapy in osteoarthritis of the hip: a randomized clinical trial.
Arthritis & Rheumatism (Arthritis Care & Research) 2004, 51(5):722-729.
9. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P: Extending the
CONSORT statement to randomized trials of nonpharmacologic
treatment: explanation and elaboration. Ann Intern Med 2008,
148(4):295-309.
10. Altman DG, et al: The American College of Rheumatology criteria for the
classification and reporting of osteoarthritis of the hip. Arthritis &
Rheumatism 1991, 34:505-514.
11. Altman DG, et al: Measurement of structural progression in osteoarthritis
of the hip: the Barcelona consensus group. Osteoarthritis & Cartilage 2004,
12:515-524.
12. Borkovec T, Nau S: Credibility of analogue therapy rationales. Journal of
Behavioural Therapy and Experimental Psychiatry 1972, 3:257-260.
13. Henry KD, Rosemond C, Eckert LB: Effect of number of home exercises on
compliance and performance in adults over 65 years of age. Phys Ther
1999, 79(3):270-277.
14. Crossley K, Bennell K, Green S, Cowan S, McConnell J: Physical therapy for
patellofemoral pain: a randomized, double-blinded, placebo-controlled
trial. Am J Sports Med 2002, 30(6):857-865.
15. Bennell KL, Hinman RS, Metcalf BR, Buchbinder R, McConnell J, McColl G,
Green S, Crossley KM: Efficacy of physiotherapy management of knee
joint osteoarthritis: a randomised, double blind, placebo controlled trial.
Annals of the Rheumatic Diseases 2005, 64(6):906-912.
16. Bennell K, Wee E, Coburn S, Green S, Harris A, Staples M, Forbes A,
Buchbinder R: Efficacy of standardised manual therapy and home
exercise programme for chronic rotator cuff disease: randomised
placebo controlled trial. British Medical Journal 2010, 8:340.
17. Buchbinder R, Youd JM, Green S, Stein A, Forbes A, Harris A, Bennell K,
Bell S, Wright WJ: Efficacy and cost-effectiveness of physiotherapy
following glenohumeral joint distension for adhesive capsulitis: a
randomized trial. Arthritis Rheum 2007, 57(6):1027-1037.
18. Pengel LH, Refshauge KM, Maher CG, Nicholas MK, Herbert RD, McNair P:
Physiotherapist-directed exercise, advice, or both for subacute low back
pain: a randomized trial. Ann Intern Med 2007, 146(11):787-796.
19. Bellamy N: Osteoarthritis clinical trials: candidate variables and
clinimetric properties. Journal of Rheumatology 1997, 24(4):768-778.
20. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R,
Brandt K, Dougados M, Lequesne M: Recommendations for a core set of
outcome measures for future phase III clinical trials in knee, hip, and
hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol
1997, 24(4):799-802.
21. Kellgren JH, Lawrence JS: Radiological assessment of osteo-arthrosis.
Annals of the Rheumatic Diseases 1957, 16(4):494-502.
22. Altman RD, Gold GE: Atlas of individual radiographic features in
osteoarthritis, revised. Osteoarthritis & Cartilage 2007, 15(Supplement A).
23. McConnell S, Kolopack P, Davis AM: The Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC): a review of its utility and
measurement properties. Arthritis Rheum 2001, 45(5):453-461.
24. Klassbo M, Larsson E, Mannevik E: Hip disability and osteoarthritis
outcome score. An extension of the Western Ontario and McMaster
Universities Osteoarthritis Index. Scand J Rheumatol 2003, 32(1):46-51.
25. Pua Y-H, Wrigley TW, Cowan SM, Bennell KL: Intrarater Test-Retest
Reliability of Hip Range of Motion and Hip Muscle Strength
Measurements in Persons With Hip Osteoarthritis. Archives of Physical
Medicine and Rehabilitation 2008, 89(6):1146.
Bennell et al. BMC Musculoskeletal Disorders 2010, 11:238
http://www.biomedcentral.com/1471-2474/11/238
Page 12 of 1326. Rejeski WJ, Ettinger WH Jr, Schumaker S, James P, Burns R, Elam JT:
Assessing performance-related disability in patients with knee
osteoarthritis. Osteoarthritis Cartilage 1995, 3(3):157-167.
27. Csuka M, McCarty DJ: Simple method for measurement of lower
extremity muscle strength. Am J Med 1985, 78(1):77-81.
28. Walsh M, Woodhouse LJ, Thomas SG, Finch E: Physical impairments and
functional limitations: a comparison of individuals 1 year after total knee
arthroplasty with control subjects. Phys Ther 1998, 78(3):248-258.
29. Hill KD, Bernhardt J, McGann AM, Maltese D, Berkovits D: A new test of
dynamic standing balance for stroke patients: reliability, validity and
comparison with healthy elderly. Physiotherapy Canada 1996,
48(4):257-262.
30. Dite W, Temple VA: A clinical test of stepping and change of direction to
identify multiple falling older adults. Arch Phys Med Rehabil 2002,
83(11):1566-1571.
31. Whitfield K, Buchbinder R, Segal L, Osborne RH: Parsimonious and efficient
assessment of health-related quality of life in osteoarthritis research:
validation of the Assessment of Quality of Life (AQoL) instrument. Health
Qual Life Outcomes 2006, 4:19.
32. Osborne RH, Hawthorne G, Lew EA, Gray LC: Quality of life assessment in
the community-dwelling elderly: validation of the Assessment of Quality
of Life (AQoL) Instrument and comparison with the SF-36. J Clin
Epidemiol 2003, 56(2):138-147.
33. Hawthorne G, Osborne R: Population norms and meaningful differences
for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public
Health 2005, 29(2):136-142.
34. Washburn RA, Smith KW, Jette AM, Janney CA: The Physical Activity Scale
for the Elderly (PASE): development and evaluation. J Clin Epidemiol 1993,
46(2):153-162.
35. Tudor-Locke C, Williams JE, Reis JP, Pluto D: Utility of pedometers for
assessing physical activity: construct validity. Sports Med 2004,
34(5):281-291.
36. Tudor-Locke C, Williams JE, Reis JP, Pluto D: Utility of pedometers for
assessing physical activity: convergent validity. Sports Med 2002,
32(12):795-808.
37. Tudor-Locke C, Burkett L, Reis JP, Ainsworth BE, Macera CA, Wilson DK: How
many days of pedometer monitoring predict weekly physical activity in
adults? Prev Med 2005, 40(3):293-298.
38. Lorig K, Chastain RL, Ung E, Shoor S, Holman HR: Development and
evaluation of a scale to measure perceived self-efficacy in people with
arthritis. Arthritis Rheum 1989, 32(1):37-44.
39. Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L:
The Pain Catastrophizing Scale: further psychometric evaluation with
adult samples. J Behav Med 2000, 23(4):351-365.
40. Rosenstiel AK, Keefe FJ: The use of coping strategies in chronic low back
pain patients: relationship to patient characteristics and current
adjustment. Pain 1983, 17(1):33-44.
41. Keefe FJ, Caldwell DS, Queen KT, Gil KM, Martinez S, Crisson JE, Ogden W,
Nunley J: Pain coping strategies in osteoarthritis patients. J Consult Clin
Psychol 1987, 55(2):208-212.
42. Jaeschke R, Singer J, Guyatt GH: Measurement of health status.
Ascertaining the minimal clinically important difference. Control Clin Trials
1989, 10(4):407-415.
43. ten Klooster PM, Drossaers-Bakker KW, Taal E, van de Laar MA: Patient-
perceived satisfactory improvement (PPSI): interpreting meaningful
change in pain from the patient’s perspective. Pain 2006, 121(1-
2):151-157.
44. Bellamy N, Carette S, Ford PM, Kean WF, le Riche NG, Lussier A, Wells GA,
Campbell J: Osteoarthritis antirheumatic drug trials. III. Setting the delta
for clinical trials–results of a consensus development (Delphi) exercise.
Journal of Rheumatology 1992, 19(3):451-457.
45. Angst F, Aeschlimann A, Stucki G: Smallest detectable and minimal
clinically important differences of rehabilitation intervention with their
implications for required sample sizes using WOMAC and SF-36 quality
of life measurement instruments in patients with osteoarthritis of the
lower extremities. Arthritis Rheum 2001, 45(4):384-391.
46. Molenberghs G, Kenward M: Missing Data in Clinical Studies. Chichester,
UK: John Wiley and Sons Ltd 2007.
47. Abbott JH, Robertson MC, McKenzie JE, Baxter GD, Theis JC, Campbell AJ:
Exercise therapy, manual therapy, or both, for osteoarthritis of the hip
or knee: a factorial randomised controlled trial protocol. Trials 2009,
10:11.
48. Stuart EA, Perry DF, Le HN, Ialongo NS: Estimating intervention effects of
prevention programs: accounting for noncompliance. Prev Sci 2008,
9(4):288-298.
49. James KE, Bloch DA, Lee KK, Kraemer HC, Fuller RK: An index for assessing
blindness in a multi-centre clinical trial: disulfiram for alcohol cessation–
a VA cooperative study. Stat Med 1996, 15(13):1421-1434.
50. Krogsboll LT, Hrobjartsson A, Gotzsche PC: Spontaneous improvement in
randomised clinical trials: meta-analysis of three-armed trials comparing
no treatment, placebo and active intervention. BMC Med Res Methodol
2009, 9:1.
51. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of
clinical trials comparing placebo with no treatment. N Engl J Med 2001,
344(21):1594-1602.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/11/238/prepub
doi:10.1186/1471-2474-11-238
Cite this article as: Bennell et al.: Efficacy of a multimodal physiotherapy
treatment program for hip osteoarthritis: a randomised placebo-
controlled trial protocol. BMC Musculoskeletal Disorders 2010 11:238.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bennell et al. BMC Musculoskeletal Disorders 2010, 11:238
http://www.biomedcentral.com/1471-2474/11/238
Page 13 of 13